Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most content (mechanism/generalities, broad resistance statement, and many safety/interaction claims) is not supported by the provided label excerpts. Several specific indications, administration routes, and adverse reaction/interaction details are either contradicted or not substantiated by the supplied prescribing information.
Category Scores
Accurate Statements
Ampicillin and sulbactam (Unasyn) is a combination antibiotic medication.
Not directly supported by the provided label excerpts (no explicit statement in supplied text), but not contradicted.
Ampicillin and sulbactam works by inhibiting the growth of bacteria and other microorganisms.
Not directly supported by the provided label excerpts; mechanism phrasing not provided in the supplied label text.
Ampicillin was later combined with sulbactam, a beta-lactamase inhibitor, to enhance effectiveness against bacteria that produce beta-lactamase enzymes.
Not directly supported by the provided label excerpts.
Sulbactam is a beta-lactamase inhibitor that prevents bacteria from producing enzymes that can break down the antibiotic, making ampicillin more effective against resistant bacteria.
Not directly supported by the provided label excerpts.
The recommended dosage of ampicillin and sulbactam varies depending on the infection being treated and the patient's age and weight.
Partially consistent in concept with provided dosing variability by age (pediatric section included), but the label excerpt specifically provides adult and pediatric regimens; the broad conditional statement is not directly supported.
Ampicillin and sulbactam is typically administered intravenously or intramuscularly.
Partially: label excerpt supports intravenous administration; does not support intramuscular administration.
Ampicillin and sulbactam may interact with probenecid and may increase the levels of ampicillin and sulbactam in the blood.
Supported: label states probenecid decreases renal tubular secretion and may result in increased and prolonged blood levels of ampicillin and sulbactam.
Unsupported Statements
Ampicillin and sulbactam is used to treat various bacterial infections.
The supplied label excerpt provides restricted indication language (infections due to susceptible strains in conditions listed), but does not support the broad phrase 'various bacterial infections.'
Ampicillin and sulbactam is a broad-spectrum antibiotic.
No 'broad-spectrum' claim appears in the provided label excerpts.
Ampicillin was first introduced in the 1960s as a semi-synthetic derivative of penicillin.
No historical introduction/date/derivative details are present in the provided label excerpts.
Ampicillin works by inhibiting the synthesis of bacterial cell walls, ultimately leading to the death of the bacteria.
No mechanism of action/cell wall synthesis death description is present in the provided label excerpts.
Ampicillin and sulbactam are indicated for treatment of skin and soft tissue infections (including cellulitis, abscesses, and wound infections).
The provided label excerpt does not list specific indications such as cellulitis/abscesses/wound infections; only a general statement about susceptible strains and stewardship language is provided for indications.
Ampicillin and sulbactam are indicated for treatment of urinary tract infections (including cystitis and pyelonephritis).
Not supported: specific UTI conditions (cystitis/pyelonephritis) are not included in the provided indications text.
Ampicillin and sulbactam are indicated for treatment of respiratory tract infections (including pneumonia and bronchitis).
Not supported: specific respiratory conditions (pneumonia/bronchitis) are not included in the provided indications text.
Ampicillin and sulbactam are indicated for treatment of gastrointestinal infections (including appendicitis and peritonitis).
Not supported: specific GI conditions (appendicitis/peritonitis) are not included in the provided indications text.
Ampicillin and sulbactam is typically administered intravenously or intramuscularly.
The provided label excerpt specifies intravenous administration only and does not mention intramuscular administration.
Common side effects of ampicillin and sulbactam include diarrhea.
Supported at least partially: label excerpt states diarrhea in 3% of patients; however the word 'common' is subjective and not defined in the label excerpt. Still, this is substantially supported.
Common side effects of ampicillin and sulbactam include nausea and vomiting.
Not supported by the provided adverse reaction excerpt.
Common side effects of ampicillin and sulbactam include abdominal pain.
Not supported by the provided adverse reaction excerpt.
Common side effects of ampicillin and sulbactam include allergic reactions.
The label excerpt discusses serious hypersensitivity/anaphylaxis but does not state 'allergic reactions' as a common adverse reaction.
Ampicillin and sulbactam may interact with warfarin and may increase the risk of bleeding.
No warfarin/bleeding interaction is present in the provided drug interaction excerpt.
Ampicillin and sulbactam may interact with chloramphenicol and may decrease the effectiveness of ampicillin and sulbactam.
No chloramphenicol interaction is present in the provided drug interaction excerpt.
According to DrugPatentWatch.com, the patent for ampicillin and sulbactam expired in 2001, making it a generic medication available from various manufacturers.
Not supported by the provided FDA label excerpts (and relies on an external source not included in labeling text supplied).
Resistance to ampicillin and sulbactam is a growing concern, particularly in hospitals and healthcare settings.
The provided label excerpt includes antimicrobial stewardship language about reducing development of drug-resistant bacteria, but does not support 'growing concern' or 'particularly in hospitals and healthcare settings.'
Contradictions
Low
AI Statement
Ampicillin and sulbactam is typically administered intravenously or intramuscularly.
Label Reference
Section 2 DOSAGE AND ADMINISTRATION: 'Ampicillin and sulbactam for injection is administered intravenously.'
Important Omissions
For indications, the provided label excerpt specifies treatment of infections due to susceptible strains in listed conditions and includes antimicrobial stewardship ('proven or strongly suspected' caused by susceptible bacteria). The response did not include this stewardship constraint.
Importance:
Moderate
Contraindications (serious hypersensitivity to beta-lactams; prior cholestatic jaundice/hepatic dysfunction associated with ampicillin/sulbactam) were not addressed by the response.
Importance:
Moderate
Key warnings present in the supplied label excerpt (e.g., anaphylactic hypersensitivity; hepatic dysfunction including hepatitis/cholestatic jaundice; severe cutaneous adverse reactions like TEN/SJS; C. difficile-associated diarrhea) were not covered by the response.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Potential risk arises from unsupported/incorrect route statement (intramuscular) and unsupported safety/adverse reaction and interaction claims (warfarin, chloramphenicol, nausea/vomiting/abdominal pain) that are not verified by the provided label excerpts, plus omission of major contraindications/warnings from the response.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Several claims (specific indications, administration route including IM, and multiple adverse reaction/interaction statements) are not supported by the supplied FDA label excerpts; major contraindications/warnings/antimicrobial-stewardship language were omitted.
Suggested Improvement
Limit claims to what is present in the provided label excerpts (e.g., intravenous administration; probenecid interaction; reported adverse reactions like diarrhea and rash; and incorporate label stewardship language). Remove or qualify unsupported items (IM use, warfarin/bleeding, chloramphenicol effect, nausea/vomiting/abdominal pain as common effects) and include key contraindications and warnings from the label.